Osteoprotegerin in Cardiometabolic Disorders
Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recently related to cardiovascular disease (CVD). Human studies show a positive relationship between circulating OPG, vascular damage, and CVD, and as such OPG has emerged as a potential biomarker for CVD. T...
Saved in:
Main Authors: | C. Pérez de Ciriza, A. Lawrie, N. Varo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2015/564934 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immune Activation, Immunosenescence, and Osteoprotegerin as Markers of Endothelial Dysfunction in Subclinical HIV-Associated Atherosclerosis
by: Alessandra D’Abramo, et al.
Published: (2014-01-01) -
Multigenerational family coaggregation study of obsessive-compulsive disorder and cardiometabolic disorders
by: David Mataix-Cols, et al.
Published: (2025-01-01) -
Osteoprotegerin as an Emerging Biomarker of Carotid Artery Stenosis? A Scoping Review with Meta-Analysis
by: Jerzy Chudek, et al.
Published: (2025-01-01) -
Advanced mutant receptor activator of nuclear factor kappa‐Β ligand development with low affinity for osteoprotegerin
by: Yuria Jang, et al.
Published: (2025-01-01) -
Serum Osteoprotegerin Is a Potential Biomarker of Insulin Resistance in Chinese Postmenopausal Women with Prediabetes and Type 2 Diabetes
by: Peng Duan, et al.
Published: (2017-01-01)